Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susan E Bates

Showing results (281-290 of 293) with videos related to

Pageof 30
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 15, 2009
Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphomaRichard L Piekarz, Robin Frye, Maria Turner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 19, 2017
Phase I Study of ATR Inhibitor M6620 in Combination With Topotecan in Patients With Advanced Solid TumorsAnish Thomas, Christophe E Redon, Linda Sciuto, et al.
British Journal of Haematology|April 21, 2015
Romidepsin in peripheral and cutaneous T-cell lymphoma: mechanistic implications from clinical and correlative dataSusan E Bates, Robin Eisch, Alexander Ling, et al.
Blood|January 3, 2024
Staphylococcus aureus induces drug resistance in cancer T cells in Sézary syndromeChella Krishna Vadivel, Andreas Willerslev-Olsen, Martin R J Namini, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 25, 2020
Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic AdenocarcinomaEric Van Cutsem, Margaret A Tempero, Darren Sigal, et al.
Oncoimmunology|May 13, 2022
Neoadjuvant chemoradiation alters the immune microenvironment in pancreatic ductal adenocarcinomaRobyn D Gartrell, Thomas Enzler, Pan S Kim, et al.
Nature Communications|May 15, 2021
Mitochondrial ATP fuels ABC transporter-mediated drug efflux in cancer chemoresistanceEmily L Giddings, Devin P Champagne, Meng-Han Wu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 23, 2023
<i>DPYD</i> Testing: Time to Put Patient Safety FirstSharyn D Baker, Susan E Bates, Gabriel A Brooks, et al.
Molecular Cancer Therapeutics|December 28, 2023
The Methyltransferases METTL7A and METTL7B Confer Resistance to Thiol-Based Histone Deacetylase InhibitorsRobert W Robey, Christina M Fitzsimmons, Wilfried M Guiblet, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 23, 2026
International Consensus-Driven Recommendations for Patient-Reported Outcome Research Objectives in Early Phase Dose-Finding Oncology Trials: OPTIMISE-ROREmily Alger, Olalekan Lee Aiyegbusi, Amylou C Dueck, et al.
Pageof 30

Showing results (281-290 of 293) with videos related to

Sort By:
Pageof 30
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 15, 2009
Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphomaRichard L Piekarz, Robin Frye, Maria Turner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 19, 2017
Phase I Study of ATR Inhibitor M6620 in Combination With Topotecan in Patients With Advanced Solid TumorsAnish Thomas, Christophe E Redon, Linda Sciuto, et al.
British Journal of Haematology|April 21, 2015
Romidepsin in peripheral and cutaneous T-cell lymphoma: mechanistic implications from clinical and correlative dataSusan E Bates, Robin Eisch, Alexander Ling, et al.
Blood|January 3, 2024
Staphylococcus aureus induces drug resistance in cancer T cells in Sézary syndromeChella Krishna Vadivel, Andreas Willerslev-Olsen, Martin R J Namini, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 25, 2020
Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic AdenocarcinomaEric Van Cutsem, Margaret A Tempero, Darren Sigal, et al.
Oncoimmunology|May 13, 2022
Neoadjuvant chemoradiation alters the immune microenvironment in pancreatic ductal adenocarcinomaRobyn D Gartrell, Thomas Enzler, Pan S Kim, et al.
Nature Communications|May 15, 2021
Mitochondrial ATP fuels ABC transporter-mediated drug efflux in cancer chemoresistanceEmily L Giddings, Devin P Champagne, Meng-Han Wu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 23, 2023
<i>DPYD</i> Testing: Time to Put Patient Safety FirstSharyn D Baker, Susan E Bates, Gabriel A Brooks, et al.
Molecular Cancer Therapeutics|December 28, 2023
The Methyltransferases METTL7A and METTL7B Confer Resistance to Thiol-Based Histone Deacetylase InhibitorsRobert W Robey, Christina M Fitzsimmons, Wilfried M Guiblet, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 23, 2026
International Consensus-Driven Recommendations for Patient-Reported Outcome Research Objectives in Early Phase Dose-Finding Oncology Trials: OPTIMISE-ROREmily Alger, Olalekan Lee Aiyegbusi, Amylou C Dueck, et al.
Pageof 30